Yasho Targets INR1,500cr FY28 on 75% Utilization

Yasho Industries Limited — Q4 FY26 Earnings Call (held May 19, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “resilient performance,” “margin improving,” “strong customer confidence,” and “well positioned to deliver consistent and profitable growth.”
• Forward-looking language is confident and specific: “target over 75% utilization in FY ’27,” “capex of INR125 crores… completely funded through internal accruals,” and INR1,500 crores revenue by FY ’28.

2. Key Themes from Management Commentary

• Macro headwinds acknowledged, but execution emphasized: price disturbance, geopolitical tension, supply chain volatility, and cautious procurement are cited as demand/pricing drags, yet results are described as resilient.
• Utilization as the central lever for margin expansion:
• FY26 utilization cited as above 60%, with a target of >75% in FY27 to drive EBITDA margin expansion.
• Industrial Chemicals as the growth engine:
• Industrial Chemical segment is stated as 87% of revenue (quarter and full year).
• Long-term customer agreement improves visibility:
• A 15-year long-term agreement secured; INR51.4 crores advance received; revenue from this expected to start FY28.
• R&D and manufacturing platform strengthening:
• R&D facility completed Oct ’25 and is now operational.
• Additional manufacturing lines in high-growth categories are being commercialized.
• Working capital and balance sheet discipline:
• Cash from operations INR152.75 crores in FY26.
• Debt-to-EBITDA improved to 3.75x (from 4.70x in FY25).
• Prepaid INR23.30 crores of FY27 liabilities.

3. Q&A Analysis

Theme A: FY28 revenue target (INR1,500 cr) — drivers & visibility

• Core questions:
• Is the INR1,500 crores revenue target by FY28 achievable? What fundamentally drives it?
• What portion is tied to utilization ramp vs the long-term contract?
• Management response:
• Confidence tied to utilization reaching “optimal, 85% to 90%” by FY28 plus the special project (advance received) starting commercial operations in FY28.
• Mentions working on performance chemicals and “new molecules,” but avoids naming.
• Assessment (evasive/partial):
• Does not provide a clear revenue bridge (capacity additions → volume → revenue) beyond utilization and the contract.
• “Molecules” are described broadly; no specificity on categories.

Theme B: Margins outlook (17–19% band vs potential >20%)

• Core questions:
• Is EBITDA margin guidance still within historical 17–19%? Any color on 20%+?
• Management response:
• Says they expect “at least 2%, 3% higher EBITDA compared to this year” driven by cost rationalization from utilization beyond 70%.
• Also states gross margin guidance elsewhere: “40% to 42%”.
• Assessment:
• Stronger than prior “range” language, but still framed as relative improvement rather than a firm numeric EBITDA% target.

Theme C: Demand geography & utilization ramp despite Europe slowdown / Middle East disruptions

• Core questions:
• How to achieve 75% utilization given Europe slowdown and supply-side disruptions (Strait of Hormuz mention)?
• Outlook for Americas/Europe.
• Management response:
• Europe slowdown acknowledged, but balanced with:
  • demand improving in some segments,
  • ramping in Americas,
  • expansion into Asian market (not previously highly penetrated).
• Assessment:
• Qualitative mitigation; no quantified demand/order backlog provided.

Theme D: Tariffs, pricing power, and sustainability of pricing

• Core questions:
• How much did currency/tariffs impact revenue and margins?
• Are price increases sustainable? What happens if prices normalize?
• Management response:
• Claims growth is volume-led; currency depreciation impact is “very, very minor” due to import offset.
• Credits margin resilience to sourcing team maneuvering, product mix, and avoiding low-margin products.
• On pricing sustainability: explicitly hedges—“I don’t have a crystal ball… absolutely no idea.”
• Assessment (notable):
• Strong admission of uncertainty on pricing normalization, contrasting with confident utilization/margin ramp.

Theme E: Contract structure, CDMO vs pure chemical model

• Core questions:
• Is strategy shifting toward CDMO model?
• What is the nature of the long-term contract (customer-funded capex, visibility)?
• Management response:
• Denies CDMO: “Yasho is not governed for the CDMO kind of work.”
• Clarifies they make pure chemicals only; customers formulate.
• On contract: customer funds capex (advance received); management emphasizes technical capability and customer commitment.
• Assessment:
• Clear positioning; however, contract economics (margin profile) remain NDA-bound.

Theme F: Working capital and inventory

• Core questions:
• Working capital days increased—what changed?
• Inventory levels and plans to reduce days.
• Management response:
• Working capital days: down from ~215–216 days (FY25) to ~190 days today.
• Stock helped navigate raw material supply challenges; wants to reduce gradually to 175–170 days in 6–12 months.
• Assessment:
• Provides directional plan but avoids explaining the exact drivers of the increase beyond “stock blessing in disguise.”

Theme G: Capex breakdown and funding

• Core questions:
• FY27 capex amount and what it funds; share related to strategic contract vs company-funded.
• Management response:
• FY26 capex breakdown: INR75 cr total (R&D ~25, Pakhajan ~40–42, Vapi ~7–8).
• FY27 capex: INR125 cr, purely at Pakhajan, funded via internal accruals.
• States FY125 cr is separate from strategic contract capex: “INR125 crores has nothing to do with strategic.”
• Assessment:
• More transparent here than on revenue/molecule specifics.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Utilization targets
• FY26: above 60% utilization
• FY27: target over 75% utilization
• FY28: optimal 85% to 90% utilization
• EBITDA / margin
• FY27: expects EBITDA margin expansion; specifically “at least 2%, 3% higher EBITDA compared to… this year”
• Gross margin: “40% to 42%” (and “40% to 42% should be the right guidance”)
• Revenue
• FY28: INR1,500 crores revenue target
• Capex
• FY26 capex: INR75 crores
• FY27 capex: INR125 crores, 100% funded through internal accruals
• Volume growth
• FY27: volume growth guided as 35% to 45% (also discussed as capacity utilization + volume relationship)
• Debt
• Debt-to-EBITDA “comfort zone” target: 2.5x (management “wants to draw” this comfort zone)

Implicit signals (qualitative)

• Demand visibility improving due to long-term agreement and customer engagement.
• Industrial Chemicals expected to remain the key growth driver.
• Pricing volatility persists, but management believes operational efficiencies and mix will protect margins.
• Geographic diversification (Americas + Asia) is positioned as the utilization/risk mitigation lever.

5. Standout Statements (direct / high-signal)

• Utilization-driven growth/margins:
• “We target over 75% utilization in FY ’27, supporting EBITDA margin expansion.”
• “Utilize our assets by FY ’28… 85% to 90% that will drive us.”
• Long-term contract visibility:
• “A key milestone was securing a 15-year long-term agreement… additional funding of INR51.4 crores has already been received.”
• “We expect the revenue from this to start realizing in FY ’28.”
• Capex funding confidence:
• “For FY ’27, the company has planned a capex of INR125 crores, which will be completely funded through internal accruals.”
• Uncertainty on pricing normalization (credibility-relevant):
• “I don’t have a crystal ball… absolutely no idea.”
• Clear strategic positioning (not CDMO):
• “Yasho is not governed for the CDMO kind of work… we are purely chemical producers.”
• Margin improvement mechanism:
• “…operational efficiencies when we are driving up the utilization beyond 70%, we should able to rationalize a lot of cost.”

6. Red Flags / Positive Signals

Red flags
– Pricing outlook uncertainty is explicit (“crystal ball” / “no idea”), yet margin and revenue ramps are discussed with high confidence.
– Revenue bridge is light: INR1,500 cr FY28 relies on utilization + contract, but no detailed capacity-to-revenue math or segment-wise revenue/molecule contribution.
– Some answers remain NDA/avoidance-based (molecules/categories, contract margin profile, customer-funded capex rationale).

Positive signals
– Balance sheet improvement: debt-to-EBITDA improved to 3.75x; cash from operations INR152.75 cr.
– Utilization and margin linkage is consistent across multiple Q&A responses.
– Capex funding clarity: FY27 capex funded via internal accruals.
– Working capital improvement directionally positive (190 days vs 215–216).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current (Q4 FY26): more confident/constructive—focus on utilization ramp to 75% and capex funded internally; stronger “resilient performance” framing.
• Prior calls:
• Q3 FY26 (Feb 2026): “steady and broad-based improvement,” but still emphasizes macro uncertainty and operational containment.
• Q2 FY26 (Nov 2025): more defensive—tariff pressures, inventory buildup, and guidance was already being tempered (e.g., revenue guidance reduced due to tariff).
• Q1 FY26 (Jul 2025): optimistic about price stabilization and growth trajectory; less explicit about severe supply-chain timing issues.
• Shift classification: More Optimistic
• Management now gives clearer quantitative targets (75% utilization, INR125 cr capex, FY28 revenue) and less “wait and watch” on demand conversion.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q3 FY26, Feb 2026): FY28 revenue potential ~INR1,500 crores at ~40% utilization of Pakhajan (framed as scaling with LTSA + new lines).
• What happened / current call:
• Current call still targets INR1,500 crores FY28, but now emphasizes utilization 85–90% as the key driver (not 40%).
• Flag: ⏳ Delayed / Narrative shift (utilization basis changed)

• Not necessarily “missed,” but the utilization framing materially changed, reducing comparability.

• Past statement (Q2 FY26, Nov 2025): LTSA plant operational targeted for Q4 FY27; advance received; guidance was under tariff stress.

• Current call:
• Long-term contract revenue realization expected FY28; commercial operation timing referenced as FY28.

• Flag: ⏳ Delayed / timing moved later (from Q4 FY27 operational to FY28 revenue realization).

• Past statement (Q2 FY26, Nov 2025): inventory normalization plan to reduce working capital days (aims like 160–175 days).

• Current call: working capital days ~190 today, aiming 175–170 in 6–12 months.
• Flag: ⏳ Delayed (improvement ongoing but not yet at earlier targets).

c. Narrative Shifts

• Utilization story strengthened and re-centered:
• Earlier calls discussed utilization constraints due to tariffs/export restrictions; now it’s framed as a planned ramp with targets (75% FY27, 85–90% FY28).
• CDMO narrative appears to be a response to investor perception:
• Prior calls focused on specialty/performance chemicals and R&D; current call explicitly denies CDMO and clarifies “pure chemicals.”
• Pricing uncertainty acknowledged more explicitly now:
• Earlier calls were more about stabilization; current call admits inability to predict price normalization.

d. Consistency & Credibility Signals

• Medium credibility
• Strength: consistent emphasis on volume + utilization + mix as the core levers.
• Weakness: timing and utilization assumptions for FY28 have shifted across calls (40% utilization framing vs 85–90% utilization framing), and pricing outlook remains uncertain while guidance confidence is high.

e. Evolution of Key Themes

• Demand / geography: improving sentiment and diversification (Europe/Asia/Americas) becomes more prominent over time.
• Margins: from “protect margins under tariff” (Q2) → “margin improving via mix and utilization” (Q3) → “margin expansion via utilization >70%” (Q4).
• Capex & R&D: R&D facility completion (Oct ’25) is now “fully operational,” and capex funding is clarified for FY27.
• Supply chain risk: earlier calls highlighted tariff/export delays; current call adds shipping time elongation and import delays (3–4 weeks to 8–12 weeks; US container transit 25 days to 60–70 days).

f. Additional Insights (cross-period intelligence)

• Risk is being “operationalized” rather than “marketized”:
• Management increasingly treats macro/tariff/supply disruptions as problems that can be mitigated via inventory, sourcing, and utilization planning, but simultaneously admits no visibility on pricing normalization—suggesting margin protection may depend more on execution than on favorable market pricing.
• Guidance confidence appears to be improving as contract milestones land:
• The 15-year agreement and advance receipt are now central to FY28 visibility, implying that prior tariff-driven uncertainty is being replaced by contract-driven certainty.